AndreaBozzo/ceres-open-data-index huggingface dataset:
Polyomyositis and myocarditis associated with acquired toxoplasmosis in an immunocompetent girl

Background
          Acquired toxoplasmosis more frequently goes unrecognized. Immunocompetent adults and adolescents with primary infection are generally asymptomatic, but symptoms may include malaise, fever, and lymphadenopathy. By contrast, immunocompromised patients may experience severe manifestations including encephalitis and multisystem organ failure.
        
        
          Case presentation
          We report a case of polymyositis and myocarditis in a 13-year old immunocompetent girl with toxoplasmosis. The patient presented with proximal muscle weakness, dysphagia, palms and soles rash and elevated serum levels of muscle enzymes, with liver and myocardial involvement. The diagnosis of toxoplasmosis was confirmed by serology. The patient was treated with prednisolone and had an excellent outcome. During a follow-up period of four years no relapses occurred and antibody levels to the T. gondii significantly decreased.
        
        
          Conclusions
          Although several previous cases of toxoplasmosis occuring in association with polymyositis have been described in the literature such a wide spectrum of acute toxoplasmosis is rather unusual in immunocompetent adolescents. The relationship between T. gondii and polymyositis remains obscure. Appropriate investigation should be performed in every case of polymyositis not only for the appropriate treatment but also for further elucidation of this relationship.
If Data Standards Follow Maslow’s Hierarchy of Needs, Are We Ready for Safety?

In the 1940s, renowned psychologist Abraham Maslow first published his work on human motivation. Maslow believed that human beings were motivated to fulfill certain needs. Further, he hypothesized that it was only when basic needs were met that individuals could move on to achieve higher-level goals. It is useful to think of data system needs according to a similar hierarchy—by meeting basic functioning requirements before systems can reasonably be expected to perform more advanced functions.

This webinar will examine the experience of Maryland’s child welfare agencies and the data standards challenges they face, from counting child protective services and in-home cases, to counting children in out-of-home care, and to assuring that their Statewide Automated Child Welfare Information System is meeting minimum data standards for Federal reporting (i.e., the National Child Abuse and Neglect Data System, the Adoption and Foster Care Analysis and Reporting System, caseworker visitation, and the National Youth in Transition Database). But among all of Maryland's challenges, none have been more daunting than client identification and establishing basic interagency interfaces.

We will present stories of frustration from Maryland child welfare agencies about the problems related to these very basic data standards. While resolutions to these problems have been elusive for Maryland, the webinar will describe how—through the implementation of IT modernization efforts—the State hopes to address these vexing challenges.

The speakers for this webinar will be David Ayer, director, Research, Evaluation and Systems Development, Maryland Department of Health and Human Services, as well as members of his team.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 526958: ortho,para'-alpha-Hydroxydinitrodiphenylacetic acid, methyl ester

Chemical compound data from PubChem database. IUPAC Name: methyl 2-hydroxy-2-(2-nitrophenyl)-2-(4-nitrophenyl)acetate. Molecular Formula: C15H12N2O7. Molecular Weight: 332.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Hydrocortisone valerate

Hydrocortisone Valerate is a prescription topical ointment containing 0.2% hydrocortisone valerate, a corticosteroid that helps reduce inflammation and itching from skin conditions. Manufactured by Cosette Pharmaceuticals, Inc., it's available in 15g, 45g, and 60g tubes. This information was generated using AI and is provided for informational and research purposes only.
Minneapolis: Drug-Related Emergency Department Visits, 2004-2011 - Adverse Reactions

Excel file with estimates, rates, relative standard errors, trends and confidence intervals, covering 2004-2011 for emergency department visits involving adverse reactions in the Minneapolis metropolitan area. It includes ED visits in which an adverse health consequence (e.g., side effects or an allergic reaction) resulted when taking prescription drugs, over-the-counter medications, or dietary supplements as prescribed or recommended.  This analytic category does not include drug misuse or abuse.File includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol.  Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology.Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
Assessment of dermal sensitization by nickel salts in a novel humanized TLR-4 mouse model

Nickel is one of the most common contact allergens worldwide. Despite this prevalence, many of the underlying immunological mechanisms responsible for nickel allergy remain unclear. This knowledge gap is partially attributable to the inherent resistance of laboratory rodents (mice and rats) to dermal sensitization with nickel salts. The fundamental goal of this study was to assess the potential utility of the novel humanized Toll-like receptor-4 (hTLR-4) mouse model for use in future in vivo studies of nickel allergy. Accordingly, hTLR-4 positive and negative mice of both sexes were first incorporated into a Local Lymph Node Assay (LLNA) to evaluate dermal sensitization following topical exposure to soluble nickel salts (NiSO4). The ensuing immune responses were then characterized further by incorporating female and male hTLR-4 positive mice into a non-radioactive endpoint-based assay. Utilizing the same exposure scheme as in the LLNA, mice were euthanized following exposure and the auricular lymph nodes, spleen, and blood were collected to assess various immunological parameters associated with allergy and ACD.
Texas: 2011-2012 NSDUH

This report presents Texas\'s estimates for 25 measures of substance use and mental health based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Compound 527515: Isobutyl 2-bromobutanoate

Chemical compound data from PubChem database. IUPAC Name: 2-methylpropyl 2-bromobutanoate. Molecular Formula: C8H15BrO2. Molecular Weight: 223.11. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Monthly Cumulative Number and Percent of Adults 75 Years and Older Who Received 1+ RSV Vaccination Doses by Jurisdiction, United States

Monthly Cumulative Percent of Adults 75 Years and Older Who Received 1+ RSV Vaccination Doses by Jurisdiction, United States.  

Respiratory Syncytial Virus (RSV) vaccination coverage for adults is assessed through U.S. jurisdictions’ Immunization Information Systems Resources (IIS) data, submitted from jurisdictions to CDC monthly in aggregate by age group. 

Monthly estimates shown are cumulative, reflecting all persons aged 75 years and older who received at least one dose of an RSV vaccine from June 21, 2023, through the end of the reporting month.*,† Cumulative estimates include any historical data reported since the previous submission. National estimates are not presented since not all U.S. jurisdictions are currently reporting their IIS data to CDC. Jurisdictions reporting data to CDC include U.S. states, some localities, and territories.
Table 21. Dependence or Abuse of Illicit Drugs or Alcohol in the Past Year among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2008, 2009, and 2010 NSDUHs

This table presents the 2008 to 2010 National Survey on Drug Use and Health (NSDUH) estimates of past year alcohol or illicit drug dependence or abuse by those aged 12 or older by State and substate regions.
Information Memorandum (IM-20-04)

This Information Memorandum (IM) provides information to grantees on the formula used to calculate allotments under the John H. Chafee Foster Care Program for Successful Transition to Adulthood (Chafee program), including information on adjustments to Fiscal Year (FY) 2019 awards and information on allotments calculated for FY 2020.

Metadata-only record linking to the original dataset. Open original dataset below.
VirOligo: a database of virus-specific oligonucleotides

VirOligo is a database of virus-specific oligonucleotides. The VirOligo database consists of two tables, Common data and Oligo data. The Oligo data table contains PCR primers and hybridization probes used for detection of viral nucleic acids and the Common data table contains the experimental conditions used in their detection. Each oligonucleotide entry contains links to PubMed, GenBank, NCBI Taxonomy databases and BLAST. As of July 2001, the VirOligo database contains a complete listing of oligonucleotides specific to viral agents associated with bovine respiratory disease that were published in English in peer-reviewed journals. The viruses are bovine herpes virus types 1, 3, 4 and 5, bovine viral diarrhea virus, bovine parainfluenza 3 virus, bovine respiratory syncytial virus, bovine adenovirus, bovine rhinovirus, bovine coronavirus, bovine reovirus, bovine enterovirus and alcelaphine herpesvirus-1. The VirOligo database is being expanded to other viruses and can be accessed through the Internet at http://viroligo.okstate.edu/.
NNDSS - Table II. Meningococcal to Pertussis

NNDSS - Table II. Meningococcal to Pertussis - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data.  Data on United States exclude counts from US territories.

Note:
These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. 

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. 

Footnotes:
 C.N.M.I.: Commonwealth of Northern Mariana Islands. 

 U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. 

* Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions. 

† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.

§ Data for meningococcal disease, invasive caused by serogroups ACWY, serogroup B, other serogroups, and unknown serogroups are available in Table I.
CMS Program Statistics - Medicare Physician, Non-Physician Practitioner & Supplier

The CMS Program Statistics - Medicare Physician, Non-Physician Practitioner and Supplier tables provide use and payment data for physicians, other practitioners, limited-licensed practitioners, and durable medical equipment, prosthetic, and orthotic (DMEPOS) suppliers. 

For additional information on enrollment, providers, and Medicare use and payment, visit the CMS Program Statistics page.

 

Below is the list of tables:


	MDCR PHYSSUPP 1.  Medicare Physicians, Non-Physician Practitioners, and Suppliers:  Utilization, Program Payments, Cost Sharing, and Balance Billing for Original Medicare Beneficiaries, by Type of Entitlement, Yearly Trend
	MDCR PHYSSUPP 2.  Medicare Physicians, Non-Physician Practitioners, and Suppliers:  Utilization, Program Payments, Cost Sharing, and Balance Billing for Original Medicare Beneficiaries, by Demographic Characteristics and Medicare-Medicaid Enrollment Status
	MDCR PHYSSUPP 3.  Medicare Physicians, Non-Physician Practitioners, and Suppliers:  Utilization, Program Payments, Cost Sharing, and Balance Billing for Original Medicare Beneficiaries, by Area of Residence
	MDCR PHYSSUPP 4.  Medicare Physicians, Non-Physician Practitioners, and Suppliers:  Utilization, Program Payments, and Balance Billing for Original Medicare Beneficiaries, by Type of Service
	MDCR PHYSSUPP 5.  Medicare Physicians, Non-Physician Practitioners, and Suppliers:  Utilization, Program Payments, and Balance Billing for Original Medicare Beneficiaries, by Place of Service
	MDCR PHYSSUPP 6.  Medicare Physicians, Non-Physician Practitioners, and Suppliers:  Utilization, Program Payments, and Balance Billing for Original Medicare Beneficiaries, by Physician Specialty
	MDCR PHYSSUPP 7.  Medicare Physicians, Non-Physician Practitioners, and Suppliers: Utilization and Program Payments for Original Medicare Beneficiaries, by Restructured BETOS Classification System (RBCS) Category and Subcategory (for data year 2022 and onward) and by BETOS Classification (for data years 2013 – 2021)
Protection against cartilage and bone destruction by systemic
		  interleukin-4 treatment in established murine type II collagen-induced
		  arthritis

Destruction of cartilage and bone are hallmarks of human rheumatoid
			 arthritis (RA), and controlling these erosive processes is the most challenging
			 objective in the treatment of RA. Systemic interleukin-4 treatment of
			 established murine collagen-induced arthritis suppressed disease activity and
			 protected against cartilage and bone destruction. Reduced cartilage pathology
			 was confirmed by both decreased serum cartilage oligomeric matrix protein
			 (COMP) and histological examination. In addition, radiological analysis
			 revealed that bone destruction was also partially prevented. Improved
			 suppression of joint swelling was achieved when interleukin-4 treatment was
			 combined with low-dose prednisolone treatment. Interestingly, synergistic
			 reduction of both serum COMP and inflammatory parameters was noted when
			 low-dose interleukin-4 was combined with prednisolone. Systemic treatment with
			 interleukin-4 appeared to be a protective therapy for cartilage and bone in
			 arthritis, and in combination with prednisolone at low dosages may offer an
			 alternative therapy in RA.
COVID-19 Tenderloin Plan Zones

<strong>A. SUMMARY</strong>
Geographic zones of the priority areas in the Tenderloin neighborhood used in the COVID-19 assessment and Tenderloin Neighborhood Plan. See more details on the plan here:
https://sf.gov/news/san-francisco-releases-tenderloin-neighborhood-safety-assessment-and-plan-covid-19

<strong>B. HOW THE DATASET IS CREATED</strong>
A team of representative City departments from the Healthy Streets Operation Center (Department of Emergency Management, Department of Public Health, Department of Homelessness and Supportive Housing, Human Rights Commission, San Francisco Police Department, San Francisco Fire Department, and Department of Public Works), SF Homeless Outreach Team, Felton Institute, and community groups and stakeholders was assembled to design and implement a robust Tenderloin Neighborhood Needs Assessment. This assessment was conducted on the morning of April 28, 2020 and consisted of multi-disciplinary teams walking each block of an area of the Tenderloin broken into six geographic zones. These zone locations are shown in the plan, and are mapped in this dataset.

<strong>C. UPDATE PROCESS</strong>
This is a reference map that will not be updated.

<strong>D. HOW TO USE THIS DATASET</strong>
These zones can be used with other datasets to track trends by zone. Note that these zones are the priority zones for the Tenderloin Plan and do not represent the entire Tenderloin Neighborhood boundary. For a boundary of the entire Tenderloin, use the analysis neighborhood boundary: https://data.sfgov.org/Geographic-Locations-and-Boundaries/Analysis-Neighborhoods/p5b7-5n3h
Hospital Cost Report Audited Data: 2022

This version of the Institutional Cost Report (ICR) has been audited by a Certified Public Accounting Firm. The ICR is a uniform report completed by New York State hospitals to report income, expenses, assets, liabilities, and statistics to the Department of Health (DOH). Under DOH regulations, (Part 86-1.2), Article 28 hospitals are required to file financial and statistical data with DOH annually. The data filed is part of the ICR and is received electronically through a secured network. This data is used to develop Medicaid rates, assist in the formulation of reimbursement methodologies, and analyze trends. For more information, check out: http://www.health.ny.gov/facilities/hospital/index.htm
Patent AT-E401143-T1: [Translated] ROLL RIGHTENING MACHINE WITH VARIABLE AXIS DISTANCE

Tractionless planishing machine has at least the first five rollers from the inlet with an inter-axis relationship on a radius identical to that of a conventional planishing machine and at least the last five rollers from the inlet with an inter-axis relationship on a radius close to that of a bending machine. The inter-axis relationship between the intermediate rollers is advantageously augmented. An independent claim is also included for: the planishing of metal strip using this planishing machine.
Vecuronium bromide

Vecuronium Bromide is a prescription injectable medication used intravenously as a neuromuscular blocker to relax muscles during surgery or intubation. Available in 10 mg and 20 mg vials as a lyophilized powder for solution, it's manufactured by Eugia US LLC under ANDA206670. This information was generated using AI and is provided for informational and research purposes only.
Patent AT-E400475-T1: [Translated] DEVICE FOR DEFORMATION CALCULATION IN MOTOR VEHICLE BUMPERS USING SEVERAL SENSORS

The device (18) for evaluating strain is provided with impact discrimination means. It comprises at least two strain sensors (20, 22) which are stacked according to the longitudinal direction of the vehicle. Each sensor (20, 22) is of a binary variety, i.e. indicates when the strain undergone exceeds a predetermined threshold which is proper to the sensor (20, 22). The sensors (20, 22) have different predetermined thresholds.
Compound 527822: 3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-ol

Chemical compound data from PubChem database. IUPAC Name: 3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-ol. Molecular Formula: C10H16O. Molecular Weight: 152.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
New York (NY)

This report presents estimates for measures of substance use and mental health based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for New York for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Compound 525647: N,N-Dimethyl-N'-phenyl-p-methoxybenzamidine

Chemical compound data from PubChem database. IUPAC Name: 4-methoxy-N,N-dimethyl-N'-phenylbenzenecarboximidamide. Molecular Formula: C16H18N2O. Molecular Weight: 254.33. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Comments on ALLHAT and doxazosin

This commentary has two purposes: to summarize the rationale, design and initial results of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) trial; and to provide a history of the response to ALLHAT that led to a civil action and a Citizens Petition that was the basis for a public hearing by the US Food and Drug Administration, in May 2001. The author concludes that the results of ALLHAT should be widely disseminated. All clinicians must be warned that initial therapy with doxazosin (and possibly other alpha1 blockers) is definitely inferior to low dose diuretic treatment for patients at high risk for cardiovascular disease, such as those enrolled in ALLHAT.
Alabama 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.
2013 CMHS Uniform Reporting System (URS) Tables for Maryland

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Tables for Maryland for 2013. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program.  State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 527350: 16,20,24-Trimethyl-hentriacontyl cyanide

Chemical compound data from PubChem database. IUPAC Name: 17,21,25-trimethyldotriacontanenitrile. Molecular Formula: C35H69N. Molecular Weight: 503.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525293: 2-(1-Chloroethylidene)hexanal

Chemical compound data from PubChem database. IUPAC Name: 2-(1-chloroethylidene)hexanal. Molecular Formula: C8H13ClO. Molecular Weight: 160.64. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.